Gyrx

GyRx is a biotechnology company focused on developing a new class of small molecule therapeutics that target G-quadruplex (G4) DNA and RNA structures. Founded by pioneers in chemical biology and functional genomics from the University of California, San Francisco (UCSF), the company leverages a proprietary platform to identify and optimize ligands for these non-canonical nucleic acid structures. By modulating G4 structures, GyRx aims to regulate the expression of key disease-driving genes that have historically been considered undruggable. The company's primary focus is in oncology, specifically targeting the promoters of oncogenes such as MYC to inhibit tumor growth and progression.